Related Experiment Video
Updated: Oct 1, 2026
Ferric Chloride-induced Murine Thrombosis Models
Published on: September 5, 2016
Antithrombotic and platelet function inhibiting effects of ML3000, a new antiinflammatory drug with Cox/5-LOX
S Tries1, S Laufer, P Radziwon
1R&D-Division, Merckle GmbH, Blaubeuren, Germany. susatrie@merckle.de
Design:
The studies reported were designed to evaluate the effects of ML3000 on platelet aggregation and platelet-induced thrombin generation in human platelet rich plasma and its antithrombotic effect in a rat thrombosis model. ML3000 is a potent inhibitor of both COX-1/2 and 5-LOX with demonstrated antiinflammatory activity and a low incidence of GI mucosal injury in animal and human studies.
Methods And Results:
The antithrombotic activity of ML3000 (10, 30 and 100 mg/kg) and aspirin (30 and 100 mg/kg) was measured in the mesenteric venules of rats using the laser-induced thrombus model. Both ML3000 and aspirin, at all doses tested, showed significant antithrombotic activity. The mean number of laser injuries necessary to induce a thrombus that blocked the vessel was 1.93 +/- 0.28 in the control group, 3.3 +/- 0.53, 3.6 +/- 0.14 or 4.07 +/- 0.37 in the groups treated with ML3000 at 10, 30 or 100 mg/kg p.o. and 3.4 +/- 0.55 or 3.9 +/- 0.3 in the groups treated with Aspirin at 30 or 100 mg/kg p.o. The antithrombotic activity in this model was significant up to 12 h post-administration of 100 mg/kg ML3000 or Aspirin. The aggregation inhibiting activity of ML3000 (1-100 microg/ml) and indomethacin (1 microg/ml) was studied using the following inducing agents: ADP (1 and 2 microM), epinephrine (25 and 50 microM), collagen (0.5 and 1 microg/ml), and the thromboxane mimetic U46619 (0.8 and 1.6 microM). Aggregation inhibitory activity was observed with ML3000 in all assays except with the higher concentration of U46619 at 1.6 microM. Indomethacin (1 microg/ml) inhibited aggregation in all assays.
Conclusions:
ML3000 has significant antithrombotic activity and a marked platelet aggregation inhibiting effect. Given its demonstrated antiinflammatory activity, platelet function inhibition, and antithrombotic effects along with a lack of effect on the GI mucosa, ML3000 may offer an alternative to the combination of a COX-2 inhibitor and aspirin in arthritis patients at risk for cardiovascular disease.
Insights
ML3000 demonstrates significant antithrombotic and antiplatelet aggregation effects, comparable to aspirin. This COX-1/2 and 5-LOX inhibitor shows promise as an alternative for arthritis patients at risk of cardiovascular disease.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Inflammation Studies
Background:
- ML3000 is a dual inhibitor of cyclooxygenase (COX)-1/2 and 5-lipoxygenase (5-LOX).
- It exhibits anti-inflammatory properties with a low incidence of gastrointestinal mucosal injury.
- Platelet aggregation and thrombus formation are key factors in cardiovascular disease.
Purpose of the Study:
- To evaluate the antithrombotic effects of ML3000 in a rat model.
- To assess the impact of ML3000 on platelet aggregation and thrombin generation in human samples.
- To compare ML3000's efficacy with aspirin.
Main Methods:
- Antithrombotic activity was assessed using a laser-induced thrombus model in rat mesenteric venules.
- Platelet aggregation was studied in human platelet-rich plasma using various agonists (ADP, epinephrine, collagen, U46619).
- ML3000 and aspirin efficacy were compared at different dosages.
Main Results:
- ML3000 and aspirin exhibited significant dose-dependent antithrombotic activity in rats.
- ML3000 effectively inhibited platelet aggregation induced by ADP, epinephrine, and collagen.
- Antithrombotic effects were observed up to 12 hours post-administration for both ML3000 and aspirin at high doses.
Conclusions:
- ML3000 possesses significant antithrombotic and platelet aggregation inhibitory properties.
- Its anti-inflammatory and antiplatelet effects, coupled with GI safety, suggest potential as an alternative to COX-2 inhibitors plus aspirin for arthritis patients.
- ML3000 may offer a safer therapeutic option for managing cardiovascular risk in specific patient populations.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
01:27Peripheral Artery Disease III: Interprofessional Care